Tharimmune announces positive data with novel biparatopic pd-1/vegf and multispecific her2/her3 biologics leveraging proprietary epiclick(tm) technology

Bridgewater, nj / access newswire / april 7, 2025 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with hs1940, a dual-target multispecific biologic engineered to bind to both programmed death-1 (pd-1) and vascular endothelial growth factor (vegf), and hs3215, a dual-target biologic binding to human epidermal growth factors 2 (her2) and 3 (her3) receptors. using its proprietary epiclick™ technology, a versatile multispecific antibody engineering platform, hs1940 and hs3215 represent a key expansion of tharimmune's product pipeline and underscores the company's commitment to addressing unmet needs.
THAR Ratings Summary
THAR Quant Ranking